{"nctId":"NCT03029689","briefTitle":"Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY","startDateStruct":{"date":"2017-07-28","type":"ACTUAL"},"conditions":["HIV"],"count":61,"armGroups":[{"label":"Current ART + Raltegravir","type":"EXPERIMENTAL","interventionNames":["Drug: Raltegravir","Drug: Current ART"]},{"label":"Current ART + placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Current ART"]}],"interventions":[{"name":"Raltegravir","otherNames":["NP"]},{"name":"Placebo","otherNames":["NP"]},{"name":"Current ART","otherNames":["NP"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Documented HIV infection\n3. Stable 3-drug antiretroviral treatment including PI/r/c or NNRTI for at least 6 months.\n4. Plasma HIV-1 RNA load \\<50 copies/mL for at least 12 months.\n5. Signed Informed Consent\n\nExclusion Criteria:\n\n1. PI/r monotherapy\n2. INSTI therapy during the previous 6 months\n3. Evidence of previous INSTI resistance\n4. Creatine clearance \\<50 mL/min\n5. Child- Pugh B or C\n6. History of active uncontrolled GI disorders or diseases including:\n\n   6.1. Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the previous 5 years.\n\n   6.2. Any major bowel resection at any time.\n\n   6.3. Any chronic digestive disease such as peptic ulcer, Crohn's disease, ulcerative colitis, coeliac disease, confirmed intolerance to lactose or indeterminate colitis.\n\n   6.4. Persistent infectious gastroenteritis, colitis or gastritis; persistent or chronic diarrhea of unknown etiology; Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated)\n\n   6.5. Irritable bowel syndrome (moderate-severe)\n\n   6.6. Chronic constipation\n\n   6.7. Active proctitis\n7. Antibiotic therapy within the previous 2 months\n8. In women, pregnancy or breastfeeding\\*.\n\n   * Female subjects of childbearing potential must not be pregnant, not be planning a pregnancy or breast-feeding. Sexually active women must be willing to use two approved methods of contraception (including condoms, diaphragm, spermicides, hormonal methods and/or intrauterine devices) from baseline until the end of the clinical trial. Sexually active men in heterosexual relationships must be willing to use two approved method of contraception with their partners from baseline until the end of the clinical trial.\n   * condom use is considered as an additional method of contraception only and cannot be the only method of contraception used as not been considered an effective method by the Clinical Trial Facilitation Group (CTFG) guidelines.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bacterial Gene Richness (Observed Unique Genes). Analysis of the Composition, Structure and Function of the Intestinal Microbiome. *","description":"-\\* Structure and composition of the microbiome. DNA will be extracted and purified from fecal samples and cryopreserved at -80ºC until amplification. The purified DNA will be amplified using Illumina-tagged primers to amplify the V3 and V4 16S ribosomal DNA (rDNA) regions. PCR reactions will be performed in triplicate to preserve diversity. Pooled triplicates will be sequenced ensuring adequate sampling depth.\n\n-Function of the bacteriome. The gene content will be inferred from the abundance of each bacteria in the intestinal bacteriome according to the 16S rDNA information","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"768358","spread":null},{"groupId":"OG001","value":"730732","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"767756","spread":null},{"groupId":"OG001","value":"808911","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"724452","spread":null},{"groupId":"OG001","value":"777452","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"718824","spread":null},{"groupId":"OG001","value":"860913","spread":null}]}]}]},{"type":"SECONDARY","title":"Association of the Gut Microbiome With Inflammation Markers","description":"IL-6, IP-10","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":null},{"groupId":"OG001","value":"1.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":null},{"groupId":"OG001","value":"1.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":null},{"groupId":"OG001","value":"1.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.28","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102.99","spread":null},{"groupId":"OG001","value":"97.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.7","spread":null},{"groupId":"OG001","value":"108.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104.6","spread":null},{"groupId":"OG001","value":"99.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"106.43","spread":null},{"groupId":"OG001","value":"108.55","spread":null}]}]}]},{"type":"SECONDARY","title":"Association of the Gut Microbiome With Coagulation","description":"D-Dimer","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.155","spread":null},{"groupId":"OG001","value":"2.19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.14","spread":null},{"groupId":"OG001","value":"2.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":null},{"groupId":"OG001","value":"2.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Association of the Gut Microbiome With Enterocyte Damage","description":"Intestinal Fatty Acid Binding Protein (I-FABP)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.92","spread":null},{"groupId":"OG001","value":"0.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.94","spread":null},{"groupId":"OG001","value":"0.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":null},{"groupId":"OG001","value":"0.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.81","spread":null},{"groupId":"OG001","value":"1.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Association of the Gut Microbiome With Bacterial Translocation and Monocyte Activation","description":"LPS-binding protein (LBP), soluble CD14","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4238","spread":null},{"groupId":"OG001","value":"4274","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4478","spread":null},{"groupId":"OG001","value":"4313","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3879","spread":null},{"groupId":"OG001","value":"4221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4172","spread":null},{"groupId":"OG001","value":"4203","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.41","spread":null},{"groupId":"OG001","value":"2.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"2.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":null},{"groupId":"OG001","value":"2.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.48","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Fluorescence Intensity (MFI) Measure of Maturation, Activation, Exhaustion and Immune Senescence Markers in CD4+ and CD8+ T-cells","description":"CCR7, CD28, CD27, HLA-DR, CD38, PD-1, CD57","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8051","spread":null},{"groupId":"OG001","value":"8076","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26002","spread":null},{"groupId":"OG001","value":"27604","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"954","spread":null},{"groupId":"OG001","value":"990","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null},{"groupId":"OG001","value":"130","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1074","spread":null},{"groupId":"OG001","value":"1246","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"226","spread":null}]}]}]},{"type":"SECONDARY","title":"Association of the Gut Microbiome Composition and Richness With CD4 and CD8+ Counts.","description":"CD4 and CD8+ counts","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"696","spread":null},{"groupId":"OG001","value":"664","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"787","spread":null},{"groupId":"OG001","value":"668","spread":null}]}]}]},{"type":"SECONDARY","title":"Other Estimators of Richness and Diversity","description":"Shannon","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":null},{"groupId":"OG001","value":"2.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.91","spread":null},{"groupId":"OG001","value":"2.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":null},{"groupId":"OG001","value":"2.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.63","spread":null},{"groupId":"OG001","value":"2.97","spread":null}]}]}]},{"type":"SECONDARY","title":"Association of the Gut Microbiome Composition and Richness With CD4/CD8+ Cell Ratio.","description":"CD4/CD8+ cell ratio","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":null},{"groupId":"OG001","value":"0.91","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":37},"commonTop":["Adverse event not related to the treatment"]}}}